Anagrelide is an old drug, the pharmacokinetic properties of which will be improved for the GIST therapy. Anagrelide will be reformulated by using innovative silica matrix technology developed by DelSiTech. Silica is a non-toxic, natural compound of the body that dissolves naturally into body fluids.

Anagrelide has a very fast turnover rate and essential thrombocytemia patients have to take high single doses two to four times a day. Our reformulated anagrelide will be a slow-release product that will be administered subcutaneously once a week. Subcutaneous administration using a thin needle is patient-friendly and easy to do in the clinic or at home.

Find out more about DelSiTech and silica matrix technology at http://www.delsitech.com